MedPath

Recearch for the role of the action of GLP-1 on normal glucose tolerance

Not Applicable
Conditions
ormal glucose tolerance
Registration Number
JPRN-UMIN000006858
Lead Sponsor
Division of Diabetes and Enocrinology Kobe University Graduate School of Medicine
Brief Summary

Exenatide, but not liraglutide, markedly decelerated the peak of both plasma glucose and serum insulin levels during the OGTT, with the peaks of both glucose and insulin concentrations occurring at 150min after test initiation with exenatide compared with 30min in the control condition or with liraglutide. Exenatide and liraglutide reduced the area under the curve for plasma glucose levels during the OGTT by similar extents, whereas that for serum insulin levels was reduced only by exenatide.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
14
Inclusion Criteria

Not provided

Exclusion Criteria

ad lib blood glucose >= 200 mg/dl hypersensitivity for the drugs pregnancy or the possibility HbA1c >= 6.1% severe renal dysfunction and liver function Considering unsuitable for this research with other reasons

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
serum blood glucose,insulin,CPR,gulucagon which are obtain from OGTT Time:0,5,10,15,30,60,90,120,150,180 min
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath